What is the projected market valuation of the Antifungal Treatment Market by 2035?

The Antifungal Treatment Market is projected to reach a valuation of 26.64 USD Billion by 2035. Read More

What was the market valuation of the Antifungal Treatment Market in 2024?

In 2024, the Antifungal Treatment Market was valued at 17.51 USD Billion. Read More

What is the expected CAGR for the Antifungal Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Antifungal Treatment Market during the forecast period 2025 - 2035 is 3.89%. Read More

Which drug class segment is anticipated to have the highest valuation by 2035?

By 2035, the Azoles segment is anticipated to reach a valuation of 8.0 USD Billion. Read More

What are the projected revenues for the parenteral route of administration by 2035?

The parenteral route of administration is projected to generate revenues of 12.64 USD Billion by 2035. Read More

Which indication is expected to dominate the Antifungal Treatment Market by 2035?

Candidiasis is expected to dominate the market with projected revenues of 7.5 USD Billion by 2035. Read More

What is the expected market size for dermatophytosis treatment by 2035?

The market size for dermatophytosis treatment is expected to reach 3.8 USD Billion by 2035. Read More

Which pathogen segment is projected to have the highest revenue by 2035?

The Candida pathogen segment is projected to achieve revenues of 5.2 USD Billion by 2035. Read More

What is the anticipated market size for hospitals and clinics as end users by 2035?

The anticipated market size for hospitals and clinics as end users is expected to be 10.5 USD Billion by 2035. Read More

Who are the key players in the Antifungal Treatment Market?

Key players in the Antifungal Treatment Market include Pfizer, Bristol-Myers Squibb, Merck & Co., and Gilead Sciences. Read More

Antifungal Treatment Market

ID: MRFR/Pharma/1097-CR

128 Pages

Nidhi Mandole

Last Updated: January 13, 2026

Antifungal Treatment Market Research Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamine, Pyrimidines, and Others), by Technology (Oral, Topical, and Parenteral), by Indication (Dermatophytosis, Aspergillosis, Candidiasis, Invasive Candidiasis, Vulvovaginal Candidiasis, Mouth/Throat/Esophageal Candidiasis, and Others), by Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, and Others), by Pathogen (Hospitals & Clinics, Dermatology Clinics, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Drug Class (USD Billion)
4.1.1 Azoles
4.1.2 Echinocandins
4.1.3 Polyenes
4.1.4 Allylamine
4.1.5 Pyrimidines
4.1.6 Others
4.2 Healthcare, BY Route of Administration (USD Billion)
4.2.1 Oral
4.2.2 Topical
4.2.3 Parenteral
4.3 Healthcare, BY Indication (USD Billion)
4.3.1 Dermatophytosis
4.3.2 Aspergillosis
4.3.3 Candidiasis
4.3.4 Invasive Candidiasis
4.3.5 Vulvovaginal Candidiasis
4.3.6 Mouth/Throat/Esophageal Candidiasis
4.3.7 Others
4.4 Healthcare, BY Pathogen (USD Billion)
4.4.1 Candida
4.4.2 Aspergillus
4.4.3 Cryptococcus
4.4.4 Coccidioides Immitis
4.4.5 Zygomycetes
4.4.6 Trichophyton
4.4.7 Others
4.5 Healthcare, BY End User (USD Billion)
4.5.1 Hospitals & Clinics
4.5.2 Dermatology Clinics
4.5.3 Others
4.6 Healthcare, BY Region (USD Billion)
4.6.1 North America
4.6.1.1 US
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 UK
4.6.2.3 France
4.6.2.4 Russia
4.6.2.5 Italy
4.6.2.6 Spain
4.6.2.7 Rest of Europe
4.6.3 APAC
4.6.3.1 China
4.6.3.2 India
4.6.3.3 Japan
4.6.3.4 South Korea
4.6.3.5 Malaysia
4.6.3.6 Thailand
4.6.3.7 Indonesia
4.6.3.8 Rest of APAC
4.6.4 South America
4.6.4.1 Brazil
4.6.4.2 Mexico
4.6.4.3 Argentina
4.6.4.4 Rest of South America
4.6.5 MEA
4.6.5.1 GCC Countries
4.6.5.2 South Africa
4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Pfizer (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Bristol-Myers Squibb (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Merck & Co. (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Gilead Sciences (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Novartis (CH)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Astellas Pharma (JP)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Bayer (DE)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 GlaxoSmithKline (GB)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Sanofi (FR)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY DRUG CLASS
6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.5 US MARKET ANALYSIS BY INDICATION
6.6 US MARKET ANALYSIS BY PATHOGEN
6.7 US MARKET ANALYSIS BY END USER
6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.10 CANADA MARKET ANALYSIS BY INDICATION
6.11 CANADA MARKET ANALYSIS BY PATHOGEN
6.12 CANADA MARKET ANALYSIS BY END USER
6.13 EUROPE MARKET ANALYSIS
6.14 GERMANY MARKET ANALYSIS BY DRUG CLASS
6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.16 GERMANY MARKET ANALYSIS BY INDICATION
6.17 GERMANY MARKET ANALYSIS BY PATHOGEN
6.18 GERMANY MARKET ANALYSIS BY END USER
6.19 UK MARKET ANALYSIS BY DRUG CLASS
6.20 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.21 UK MARKET ANALYSIS BY INDICATION
6.22 UK MARKET ANALYSIS BY PATHOGEN
6.23 UK MARKET ANALYSIS BY END USER
6.24 FRANCE MARKET ANALYSIS BY DRUG CLASS
6.25 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.26 FRANCE MARKET ANALYSIS BY INDICATION
6.27 FRANCE MARKET ANALYSIS BY PATHOGEN
6.28 FRANCE MARKET ANALYSIS BY END USER
6.29 RUSSIA MARKET ANALYSIS BY DRUG CLASS
6.30 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.31 RUSSIA MARKET ANALYSIS BY INDICATION
6.32 RUSSIA MARKET ANALYSIS BY PATHOGEN
6.33 RUSSIA MARKET ANALYSIS BY END USER
6.34 ITALY MARKET ANALYSIS BY DRUG CLASS
6.35 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.36 ITALY MARKET ANALYSIS BY INDICATION
6.37 ITALY MARKET ANALYSIS BY PATHOGEN
6.38 ITALY MARKET ANALYSIS BY END USER
6.39 SPAIN MARKET ANALYSIS BY DRUG CLASS
6.40 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.41 SPAIN MARKET ANALYSIS BY INDICATION
6.42 SPAIN MARKET ANALYSIS BY PATHOGEN
6.43 SPAIN MARKET ANALYSIS BY END USER
6.44 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
6.45 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.46 REST OF EUROPE MARKET ANALYSIS BY INDICATION
6.47 REST OF EUROPE MARKET ANALYSIS BY PATHOGEN
6.48 REST OF EUROPE MARKET ANALYSIS BY END USER
6.49 APAC MARKET ANALYSIS
6.50 CHINA MARKET ANALYSIS BY DRUG CLASS
6.51 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.52 CHINA MARKET ANALYSIS BY INDICATION
6.53 CHINA MARKET ANALYSIS BY PATHOGEN
6.54 CHINA MARKET ANALYSIS BY END USER
6.55 INDIA MARKET ANALYSIS BY DRUG CLASS
6.56 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.57 INDIA MARKET ANALYSIS BY INDICATION
6.58 INDIA MARKET ANALYSIS BY PATHOGEN
6.59 INDIA MARKET ANALYSIS BY END USER
6.60 JAPAN MARKET ANALYSIS BY DRUG CLASS
6.61 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.62 JAPAN MARKET ANALYSIS BY INDICATION
6.63 JAPAN MARKET ANALYSIS BY PATHOGEN
6.64 JAPAN MARKET ANALYSIS BY END USER
6.65 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
6.66 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.67 SOUTH KOREA MARKET ANALYSIS BY INDICATION
6.68 SOUTH KOREA MARKET ANALYSIS BY PATHOGEN
6.69 SOUTH KOREA MARKET ANALYSIS BY END USER
6.70 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
6.71 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.72 MALAYSIA MARKET ANALYSIS BY INDICATION
6.73 MALAYSIA MARKET ANALYSIS BY PATHOGEN
6.74 MALAYSIA MARKET ANALYSIS BY END USER
6.75 THAILAND MARKET ANALYSIS BY DRUG CLASS
6.76 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.77 THAILAND MARKET ANALYSIS BY INDICATION
6.78 THAILAND MARKET ANALYSIS BY PATHOGEN
6.79 THAILAND MARKET ANALYSIS BY END USER
6.80 INDONESIA MARKET ANALYSIS BY DRUG CLASS
6.81 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.82 INDONESIA MARKET ANALYSIS BY INDICATION
6.83 INDONESIA MARKET ANALYSIS BY PATHOGEN
6.84 INDONESIA MARKET ANALYSIS BY END USER
6.85 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
6.86 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.87 REST OF APAC MARKET ANALYSIS BY INDICATION
6.88 REST OF APAC MARKET ANALYSIS BY PATHOGEN
6.89 REST OF APAC MARKET ANALYSIS BY END USER
6.90 SOUTH AMERICA MARKET ANALYSIS
6.91 BRAZIL MARKET ANALYSIS BY DRUG CLASS
6.92 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.93 BRAZIL MARKET ANALYSIS BY INDICATION
6.94 BRAZIL MARKET ANALYSIS BY PATHOGEN
6.95 BRAZIL MARKET ANALYSIS BY END USER
6.96 MEXICO MARKET ANALYSIS BY DRUG CLASS
6.97 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.98 MEXICO MARKET ANALYSIS BY INDICATION
6.99 MEXICO MARKET ANALYSIS BY PATHOGEN
6.100 MEXICO MARKET ANALYSIS BY END USER
6.101 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
6.102 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.103 ARGENTINA MARKET ANALYSIS BY INDICATION
6.104 ARGENTINA MARKET ANALYSIS BY PATHOGEN
6.105 ARGENTINA MARKET ANALYSIS BY END USER
6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATHOGEN
6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
6.111 MEA MARKET ANALYSIS
6.112 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
6.113 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.114 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
6.115 GCC COUNTRIES MARKET ANALYSIS BY PATHOGEN
6.116 GCC COUNTRIES MARKET ANALYSIS BY END USER
6.117 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
6.118 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.119 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
6.120 SOUTH AFRICA MARKET ANALYSIS BY PATHOGEN
6.121 SOUTH AFRICA MARKET ANALYSIS BY END USER
6.122 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
6.123 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.124 REST OF MEA MARKET ANALYSIS BY INDICATION
6.125 REST OF MEA MARKET ANALYSIS BY PATHOGEN
6.126 REST OF MEA MARKET ANALYSIS BY END USER
6.127 KEY BUYING CRITERIA OF HEALTHCARE
6.128 RESEARCH PROCESS OF MRFR
6.129 DRO ANALYSIS OF HEALTHCARE
6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
6.133 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
6.134 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
6.135 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
6.136 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
6.137 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
6.138 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
6.139 HEALTHCARE, BY PATHOGEN, 2024 (% SHARE)
6.140 HEALTHCARE, BY PATHOGEN, 2024 TO 2035 (USD Billion)
6.141 HEALTHCARE, BY END USER, 2024 (% SHARE)
6.142 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.2.3 BY INDICATION, 2025-2035 (USD Billion)
7.2.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.2.5 BY END USER, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.3.3 BY INDICATION, 2025-2035 (USD Billion)
7.3.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.3.5 BY END USER, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.4.3 BY INDICATION, 2025-2035 (USD Billion)
7.4.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.4.5 BY END USER, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.5.3 BY INDICATION, 2025-2035 (USD Billion)
7.5.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.5.5 BY END USER, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.6.3 BY INDICATION, 2025-2035 (USD Billion)
7.6.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.6.5 BY END USER, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.7.3 BY INDICATION, 2025-2035 (USD Billion)
7.7.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.7.5 BY END USER, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.8.3 BY INDICATION, 2025-2035 (USD Billion)
7.8.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.8.5 BY END USER, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.9.3 BY INDICATION, 2025-2035 (USD Billion)
7.9.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.9.5 BY END USER, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.10.3 BY INDICATION, 2025-2035 (USD Billion)
7.10.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.10.5 BY END USER, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.11.3 BY INDICATION, 2025-2035 (USD Billion)
7.11.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.11.5 BY END USER, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.12.3 BY INDICATION, 2025-2035 (USD Billion)
7.12.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.12.5 BY END USER, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.13.3 BY INDICATION, 2025-2035 (USD Billion)
7.13.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.13.5 BY END USER, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.14.3 BY INDICATION, 2025-2035 (USD Billion)
7.14.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.14.5 BY END USER, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.15.3 BY INDICATION, 2025-2035 (USD Billion)
7.15.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.15.5 BY END USER, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.16.3 BY INDICATION, 2025-2035 (USD Billion)
7.16.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.16.5 BY END USER, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.17.3 BY INDICATION, 2025-2035 (USD Billion)
7.17.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.17.5 BY END USER, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.18.3 BY INDICATION, 2025-2035 (USD Billion)
7.18.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.18.5 BY END USER, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.19.3 BY INDICATION, 2025-2035 (USD Billion)
7.19.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.19.5 BY END USER, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.20.3 BY INDICATION, 2025-2035 (USD Billion)
7.20.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.20.5 BY END USER, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.21.3 BY INDICATION, 2025-2035 (USD Billion)
7.21.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.21.5 BY END USER, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.22.3 BY INDICATION, 2025-2035 (USD Billion)
7.22.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.22.5 BY END USER, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.23.3 BY INDICATION, 2025-2035 (USD Billion)
7.23.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.23.5 BY END USER, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.24.3 BY INDICATION, 2025-2035 (USD Billion)
7.24.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.24.5 BY END USER, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.25.3 BY INDICATION, 2025-2035 (USD Billion)
7.25.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.25.5 BY END USER, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.26.3 BY INDICATION, 2025-2035 (USD Billion)
7.26.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.26.5 BY END USER, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.27.3 BY INDICATION, 2025-2035 (USD Billion)
7.27.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.27.5 BY END USER, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.28.3 BY INDICATION, 2025-2035 (USD Billion)
7.28.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.28.5 BY END USER, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.29.3 BY INDICATION, 2025-2035 (USD Billion)
7.29.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.29.5 BY END USER, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion)
7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.30.3 BY INDICATION, 2025-2035 (USD Billion)
7.30.4 BY PATHOGEN, 2025-2035 (USD Billion)
7.30.5 BY END USER, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Drug Class (USD Billion, 2025-2035)

Azoles
Echinocandins
Polyenes
Allylamine
Pyrimidines
Others

Healthcare By Route of Administration (USD Billion, 2025-2035)

Oral
Topical
Parenteral

Healthcare By Indication (USD Billion, 2025-2035)

Dermatophytosis
Aspergillosis
Candidiasis
Invasive Candidiasis
Vulvovaginal Candidiasis
Mouth/Throat/Esophageal Candidiasis
Others

Healthcare By Pathogen (USD Billion, 2025-2035)

Candida
Aspergillus
Cryptococcus
Coccidioides Immitis
Zygomycetes
Trichophyton
Others

Healthcare By End User (USD Billion, 2025-2035)

Hospitals & Clinics
Dermatology Clinics
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓